Trade Arcutis Biotherapeutics, Inc. - ARQT CFD

Arcutis Biotherapeutics, Inc. Company profile

About Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics, Inc. is a late-stage biopharmaceutical company. It is focused on developing and commercializing treatments for dermatological diseases with unmet medical needs. It harnesses its dermatology development platform to build therapies against biologically validated targets. Its dermatology development platform includes a robust pipeline with multiple clinical programs for a range of inflammatory dermatological conditions. The company’s lead program, topical roflumilast, has the potential to advance the care for plaque psoriasis of the body and scalp, atopic dermatitis and seborrheic dermatitis. It is developing roflumilast cream for the treatment of plaque psoriasis, including psoriasis in intertriginous regions, such as the groin, axillae and inframammary areas, as well as atopic dermatitis. It is also developing ARQ-252 is topical cream formulation of a potent and selective small molecule inhibitor of JAK1 and is developing it for chronic hand eczema and vitiligo.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Arcutis Biotherapeutics Inc revenues was not reported. Net loss increased 52% to $206.4M. Higher net loss reflects General and administrative - Balancing increase from $16.9M to $45.6M (expense), Research and development - Balancing val increase of 23% to $137.1M (expense), Stock-based Compensation in SGA increase from $4.4M to $15.4M (expense).